Audit of Contrast Dose and Renal Injury After Interventional Radiology Procedures (ACORN)
Project Summary
The Audit of Contrast Dose and Renal Injury After Interventional Radiology Procedures (ACORN) project aims to assess the incidence of AKI in patients who underwent IR procedures with intravascular contrast administration. Therefore, participants will be involved in collecting patient data before during and after certain IR procedures.
Project Status
Unfortunately the deadline to sign up to this project has passed.
Data collection has now been completed and data analysis is currently underway.
Project Visualiser
The details
Study design
Multicentre retrospective cohort study
Study participants
962 patients were identified from 12 sites across the UK
Primary objective
1.To evaluate the incidence of Contrast-Associated Acute Kidney Injury (CA-AKI) in a cohort of patients across the UK - these were patients who received intra-arterial administration of iodinated contrast during Interventional Radiology procedures
2.To identify risk factors associated with CA-AKI
Inclusion criteria
Consecutive adult patients (18 or older) who underwent the following IR/endovascular procedures (emergency or elective) involving intra-arterial administration of iodinated contrast agents:
Aortic cases (EVARs, TEVARs, FEVARs), Peripheral Arterial Disease cases (angioplasty, stenting, thrombolysis, thrombectomy), patients who have a baseline pre-procedure creatinine value recorded (maximum 3 months pre-procedure, 1 week before if diagnosed CKD), Patients who have a post-procedure creatinine value recorded within 48 hrs (+/-12 hours), date of procedure from (01/01/2022 to 30/12/2022)
Exclusion criteria
Patients who underwent an IR procedure not mentioned above. Patients who had IV administration of contrast media within 48 hrs before operation. Patients who underwent previous kidney transplant. Patients who have end-stage kidney disease or have undergone dialysis up to 90 days preceding procedure. Patients with end-stage heart disease or terminal cancer. Patients with an allergic reaction to contrast. Patients who might have kidney injury due to complications of the procedure. (for example in cases of EVAR where the renal arteries were covered).
Sample size
962 patients
Follow up duration
Up to 30 days post-procedure
Study period
We targeted procedures from January 1, 2022, to December 30, 2022
Presentation
/publications
Protocol presented as poster at CIRSE 2024
How to contact us
Study lead - Dr. Michael Stephanou cossteph@hotmail.com
As presented at
Team and funding
Study Management Group
Michael Stephanou- FY1 Doctor, Princess Alexandra Hospital, Harlow, UK
David Schramm- Medical Student, University of Oxford, Oxford, UK
Indrajeet Mandal- Radiology Trainee, Oxford University Hospitals, Oxford, UK
Gregory Makris – Consultant Vascular and Interventional Radiologist, Guy's and St Thomas' NHS Foundation Trust
​
Study Advisory Group
Hunain Shiwani - Interventional Radiology Registrar, Leeds Teaching Hospitals NHS Trust
Ganesh Vigneswaran - NIHR Clinical Lecturer/ Interventional Radiology Registrar, University of Southampton
Jim Zhong - Interventional Radiology Registrar, Leeds Teaching Hospitals NHS Trust